After a roughly two-year stint running Biogen’s (NASDAQQ: [[ticker:BIIB]]) dealmaking efforts, Adam Koppel is returning to his previous employer, Bain Capital. Koppel, who was named Biogen’s chief strategy officer in 2014, will step down on June 2 and head back to Bain as a managing director, where he’ll make private investments in biotech and life sciences companies. His role at Biogen will be split between CEO George Scangos, newly hired research chief Michael Ehlers, and chief financial officer Paul Clancy.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler